Altimmune (ALT) Gains from Investment Securities (2012 - 2026)
Altimmune (ALT) reported Gains from Investment Securities of $695000.0 for Q1 2026, up 1528.44% year-over-year from $42679.0 in Q1 2025, and up 2680.0% quarter-over-quarter from $25000.0 in Q4 2025.
Altimmune (ALT) Gains from Investment Securities (2012 - 2026) Analysis & Trends
Altimmune (ALT) has 14 years of Gains from Investment Securities data on file, last reported at $695000.0 in Q1 2026.
- Gains from Investment Securities for Q1 2026 came in at $695000.0, up 1528.44% year-over-year; the trailing twelve-month figure through Mar 2026 was $759000.0 (up 1678.39% YoY), and the FY2025 annual result was $11.3 million, up 70.27% from the prior year.
- Gains from Investment Securities advanced to $695000.0 in Q1 2026 per ALT's latest filing, from $25000.0 in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $8.7 million in Q3 2025 and troughed at -$305000.0 in Q4 2022.
- A 5-year average of $3.2 million and a median of $3.5 million in 2022 frame the typical range for Gains from Investment Securities.
- The sharpest annual moves came in 2022 and 2025: Gains from Investment Securities soared 22302.09% in 2022, then tumbled 99.35% in 2025.
- A 5-year view of Gains from Investment Securities shows it stood at -$305000.0 in 2022, then surged by 112.13% to $37000.0 in 2023, then slumped by 94.59% to $2000.0 in 2024, then surged by 1150.0% to $25000.0 in 2025, then jumped by 2680.0% to $695000.0 in 2026.
- Business Quant data shows ALT's Gains from Investment Securities at $695000.0 in Q1 2026, $25000.0 in Q4 2025, and $8.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Altimmune | 336.67 Mn | 336.67 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 695,000.00 |
| Mar 31, 2026 | 695,000.00 |
| Dec 31, 2025 | 25,000.00 |
| Dec 31, 2025 | 25,000.00 |
| Sep 30, 2025 | 8.66 Mn |
| Sep 30, 2025 | 8.66 Mn |
| Jun 30, 2025 | 8.10 Mn |
| Jun 30, 2025 | 8.10 Mn |
| Mar 31, 2025 | 42,679.00 |
| Mar 31, 2025 | 42,679.00 |
| Dec 31, 2024 | 2,000.00 |
| Dec 31, 2024 | 2,000.00 |
| Sep 30, 2024 | 348,533.00 |
| Sep 30, 2024 | 348,533.00 |
| Jun 30, 2024 | 6.28 Mn |
| Jun 30, 2024 | 6.28 Mn |
| Mar 31, 2024 | 6.54 Mn |
| Mar 31, 2024 | 6.54 Mn |
| Dec 31, 2023 | 37,000.00 |
| Dec 31, 2023 | 37,000.00 |